|

BGB-43395 Clinical Trials

4 actively recruiting trials across 3 locations

▼ -1 trial since June 2026

Pipeline

Phase 1: 3Phase 3: 1

Top Sponsors

  • BeOne Medicines4

Indications

  • Cancer4
  • Breast Cancer3
  • Metastatic Breast Cancer2
  • HER2-negative Breast Cancer2
  • Hormone Receptor Positive Breast Cancer2

Birmingham, Alabama2 trials

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

University of Alabama At Birmingham Hospital

Phase 1
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Alabama Oncology Princeton

Phase 3

Denver, Colorado1 trial

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sarah Cannon Research Institute (Scri) At Health One

Phase 1

Iowa City, Iowa1 trial

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

University of Iowa Hospitals and Clinics

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.